When was Miromatrix founded?

Miromatrix was founded in 2009.

Where is Miromatrix located?

Miromatrix is headquartered in Eden Prairie, United States. It is registered at Eden Prairie, Minnesota.

How many employees does Miromatrix have?

As of Mar 01, 2026, the latest employee count at Miromatrix is 50 - 199.

Is Miromatrix a funded company?

Miromatrix is a funded company, having raised a total of $51M across 12 funding rounds to date. The company's 1st funding round was a $***** Series A round.

How much is Miromatrix worth?

The last known valuation of Miromatrix was $***** as of Oct 30, 2023.

When was the latest funding round of Miromatrix?

Miromatrix's latest funding was a $***** Series C round on May 28, 2021, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.23B in funding in 2026 to date.

What is the annual revenue of Miromatrix?

Annual revenue of Miromatrix is less than $1M as on Dec 31, 2022

Where does Miromatrix rank among its competitors?

Miromatrix ranks 88th amongst 1952 active competitors, of which 450 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of Miromatrix?

Miromatrix's top competitors include Antheia, Transcenta and Akeso. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

Miromatrix - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Miromatrix Medical is developing fully biological replacement organs for the human body. Its first product is a bio mesh for hernia repair and breast reconstruction and is also trying to create human organs including the liver, lung, kidney, pancreas, and heart. The mesh is a non-cross-linked, acellular surgical mesh that is derived from the highly vascularized porcine liver. The products involve the use of technologies like the perfusion decellularization process that involves the removal of all cellular components by passing a mild detergent through the native vascular system of a biological structure (organ, bone, or tissue), this allows the generation of a scaffold or biological matrix.

Website: miromatrix.com
Social
Email ID: *****@miromatrix.com
Phone Number: +1 **********
Registered Address: Eden Prairie, Minnesota

Key Metrics

Founded Year

2009

Location

Eden Prairie, United States

Stage

Acquired

Total Funding

$51M in 12 rounds

Latest Funding Round

Series C, May 28, 2021, $*****

Last Known Valuation

$***** as on Oct 30, 2023

Investors

CareDx & 8 more

Ranked

88^th among 1952 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2022

Employee Count

50 - 199 as on Mar 01, 2026

Similar Companies

Antheia & 2658 more

Exit Details

Acquired by United Therapeutics (Oct 30, 2023)

View Miromatrix's full profile

Miromatrix is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Miromatrix Medical Inc. CIN: 271285782 , United States, Active	Dec 31, 2008	$0 - $1M (As on Dec 31, 2022)	68 (As on Dec 31, 2023)	-

Miromatrix got acquired by United Therapeutics on Oct 30, 2023 at an acquisition amount of $*****.

Click here to take a look at Miromatrix's acquisition in detail

Miromatrix has raised a total funding of $51M over 12 rounds. Its latest funding round was a Series C round on May 28, 2021 for $*****. 1 investor participated in its latest round. Miromatrix has 9 institutional investors.

Here is the list of recent funding rounds of Miromatrix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 28, 2021	3629724	Series C	8992878	2540285	9131708	3433455
Oct 16, 2019	2918301	Grant (prize money)	9832940	1950714	3536501	NIDDK
Sep 17, 2019	4346315	Grant (prize money)	4360267	2096988	2701997	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Miromatrix's funding rounds and investors

Miromatrix's employee count trend

Miromatrix has 50 - 199 employees as of Mar 26. Here is Miromatrix's employee count trend over the years:

Uncover Miromatrix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Miromatrix include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Miromatrix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
6th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
7th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
8th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
9th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
10th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, Norwest & 22 others	61/100
88th	Miromatrix 2009, Eden Prairie (United States), Acquired	Developing biologic human organs for transplantation	$51M	Lateral Capital, Gravity Fund & 7 others	51/100